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Purpose
Tyrosine kinase inhibitors (TKIs) are considered good
candidates for combination with cancer immunotherapy
due to their ability to decrease myeloid-derived suppres-
sor cells (MDSCs) in peripheral blood. However, very
little is known about the effects of TKIs on myeloid
cells in the tumor microenvironment. In this study we
evaluated the effect of combining TKIs with vaccine on
the frequency and activation of myeloid cells in the
tumor microenvironment.
Methods
Flow-cytometry analysis of tumor infiltrating myeloid
cells was performed in colon carcinoma (MC38-CEA+ in
CEA-transgenic C57BL-6 mice, n=18) and breast cancer
(4T1 in Balb-c mice, n=30). Mice received sunitinib or
sorafenib for 21 days either alone or in combination with
vaccine, which consisted of MVA-TRICOM and the
tumor-associated antigen CEA in colon and TWIST in
breast models. We evaluated granulocytes (Gr1+CD11b-),
MDSCs (Gr1+CD11b+), and tumor-associated macrophages
(TAMs, Gr1-CD11b+). Markers utilized to identify activa-
tion were FasL [1], CXCL9 [2], CD31 [3], and CD105 [4].
Results
In the MC38-CEA+ model, either TKI (sunitinib or sorafe-
nib) with or without vaccine increased the percentage of
granulocytes and MDSCs and decreased TAMs, and
increased the expression of 4 of 4 activation markers in
MDSCs and TAMs. In contrast to the colon model, in
4T1 tumors, the frequency of granulocytes, MDSCs and
TAMs were unaltered by any treatment. However, the
expression of 2 of 4 activation markers (CXCL9 and
CD105) increased in MDSCs and TAMs only when either
TKI was combined with vaccine, and not with either TKI
or vaccine alone.
Conclusions
In one model (MC38-CEA+colon), addition of vaccine to
either TKI (sunitinib or sorafenib) had no additional
effect on the frequency or activation of tumor infiltrating
myeloid cells. In another model (4T1), activation markers
on tumor infiltrating myeloid cells were elevated only
when TKIs were combined with vaccine. These studies
provide evidence that the addition of vaccine to TKI, in
some cases, enhances myeloid cell activation at the
tumor.
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